Genome editing abrogates angiogenesis in vivo

Xionggao Huang; Guohong Zhou; Wenyi Wu; Yajian Duan; Gaoen Ma; Jingyuan Song; Ru Xiao; Luk Vandenberghe; Feng Zhang; Patricia A. D’Amore; Hetian Lei

doi:10.1038/s41467-017-00140-3

Nature Communications (Jul 2017)

Genome editing abrogates angiogenesis in vivo

Xionggao Huang,
Guohong Zhou,
Wenyi Wu,
Yajian Duan,
Gaoen Ma,
Jingyuan Song,
Ru Xiao,
Luk Vandenberghe,
Feng Zhang,
Patricia A. D’Amore,
Hetian Lei

Affiliations

Xionggao Huang: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Guohong Zhou: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Wenyi Wu: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Yajian Duan: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Gaoen Ma: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Jingyuan Song: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Ru Xiao: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Luk Vandenberghe: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Feng Zhang: Broad Institute of the Massachusetts Institute of Technology and Harvard University
Patricia A. D’Amore: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School
Hetian Lei: Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-017-00140-3
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 8

Abstract

Read online

Abnormal angiogenesis causes many ocular diseases. Here the authors employ CRISPR/Cas9 gene editing technology to silence VEGFR2, a major regulator of angiogenesis, in retinal endothelium and abrogate angiogenesis in the mouse models of oxygen-induced retinopathy and laser-induced choroid neovascularization.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal